New Developments in Active Surveillance for Prostate Cancer

Video

In this peer-to-peer discussion, Dr. Loeb and Dr. Choyke discuss new developments in active surveillance for prostate cancer.

At the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 3–7 in Chicago, Stacy Loeb, MD, of the NYU Langone Medical Center in New York, New York, and Peter L. Choyke, MD, of the National Cancer Institute in Bethesda, Maryland, gave presentations during the education session “Contemporary Active Surveillance for Prostate Cancer: Do We Need Better Imaging and Molecular Testing?”

In this peer-to-peer discussion, Dr. Loeb and Dr. Choyke discuss some of the salient points from their session, including the use of magnetic resonance imaging for patient selection and follow-up and the use of new molecular markers that could signal tumor changes in patients on surveillance.

Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
Related Content